INS and type 1 diabetes mellitus: In the adjunct 2 trial over 26 weeks among 835 individuals with T1D (mean HbA1c 8.1%), adding liraglutide to capped insulin doses significantly reduced HbA1c levels and body weight compared to placebo (liraglutide 1.8 mg: −0.33%; 1.2 mg: −0.22%; 0.6 mg: −0.23%; placebo: 0.01% and mean body weight reductions were −5.1 kg, −4.0 kg, and −2.5 kg for liraglutide doses of 1.8, 1.2, and 0.6 mg, respectively, vs −0.2 kg with placebo).26